Neovascular age-related macular degeneration (nAMD) is among the leading causes of blindness worldwide. Central vision loss can progress quickly and a timely diagnosis and treatment plan are crucial for maintaining visual acuity, independence, and quality of life. In this Clinical Reflections® activity, you will be challenged to reflect back on a mismanaged case of nAMD and explore ways the patient could have been better treated. Drs. David Brown and Eric Schneider will lead you through this exercise, demonstrating the benefits and limitations of current treatment options for nAMD and reviewing recent data on novel and emerging therapies.
Upon completion of this activity, participants should be better able to:
Clinical Professor, Ophthalmology
Cullen Eye Institute, Baylor College of Medicine
Vice Chair, Research
Blanton Eye Institute, Houston Methodist Hospital
Retina Consultants of Texas
San Antonio, TX
Retina Specialist, Ophthalmology Clinic
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
David M. Brown, MD, FACS, has relevant financial relationships with 4D Molecular Therapeutics, Inc., Adverum Biotechnologies Inc., AGTC, Alexion Pharmaceuticals Inc., Annexon Inc., Apellis Pharmaceuticals Inc., Bayer AG, Biogen MA Inc., Boehringer Ingelheim, Celltrion Healthcare Co., Ltd., Chengdu Kanghong Pharmaceutical Industry Group Co., Ltd., Clearside Biomedical Inc., Coherus BioScience Inc., Gemini Therapeutics Inc., Glaukos Inc., Heidelberg Engineering, Inc., Iveric Bio, inc., Kodiak Sciences Inc., Lineage Cell Therapeutics, Inc., Molecular Partners AG, Novartis Pharma AG, Ocular Therapeutix, Inc., Ocuphire Pharma, Inc., Optos plc, Pontifax, PPD, Inc., Ray Therapeutics Inc., Regeneron Pharmaceuticals Inc., RetinAI Medical AG, Samsung Bioepis Co,Ltd., SciNeuro Therapeutics Inc., Senju Pharmaceutical Co., Ltd., Shanghai SIMR Biotechnology Co., Ltd., Smilebiotek Zhuhai Limited, Stealth BioTherapeutics Inc., Verseon International Corporation (Consultant); Adverum Biotechnologies, Inc., Aldeyra Therapeutics, Inc., Alexion Pharmaceuticals, Inc., Alimera Sciences Inc., Alkahest, Inc., Amgen Inc., Annexon, Inc., Apellis Pharmaceuticals, Inc., Aura Sub, LLC, Bayer AG, Boehringer Ingelheim, Carl Zeiss Meditec AG, Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Gemini Therapeutics Inc., Genentech/Roche, Graybug Vision, Inc., Gyroscope, Ionis Pharmaceuticals, Inc., Irenix Medical, Inc., Iveric, Bio, inc., Kodiak Sciences, LumiThera, Inc., Nanoscope Therapeutics inc., NEINH, Neurotech Services Ltd., NGM Biopharmaceuticals Inc., Novartis Pharma AG, Ocular Therapeutix, Inc., Ocuphire Pharma, Inc., Opthea Limited, Opthotech Corporation, Optos plc, Oxurion NV, Oyster Point Pharma, Inc., Regeneron Pharmaceuticals Inc., REGENXBIO Inc., Roche, Sam Chun Dang Pharm. Co., LTD., Samsung, Sandoz Inc., Senju, Santen Pharmaceutical Co., Ltd., Stealth, Unity, Xbrane Biopharma (Grant/Research Support); Adverum Biotechnologies, Inc., Clearside Biomedical Inc. (Stock/Shareholder).
Eric W. Schneider, MD, FASRS, has relevant financial relationships with Carl Zeiss Meditec AG, Notal Vision, Inc. (Consultant); 4D Molecular Therapeutics, Inc., Adverum Biotechnologies, Inc., AffaMed Therapeutics, Apellis Pharmaceuticals, Astellas Pharma Inc., Chengdu Kanghong Biotechnology Ltd., EyePoint Pharmaceuticals, Genentech Inc., Ionis Pharmaceuticals, Inc., Kodiak Sciences, Mylan N.V., NGM Biopharmaceuticals Inc., Notal Vision, Inc., Novartis, OcuTerra Therapeutics, Opthea, Oxurion NV, Priovant Therapeutics, Regeneron Pharmaceuticals Inc., REGENXBIO Inc. (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE Credit Hours
RMEI Medical Education, LLC designates this Asynchronous Online activity for a maximum of 0.5 COPE credit hour(s). Optometrists should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].
There is no fee to participate.
COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!*
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources